CTLA4 and synovial sarcoma: Furthermore, monoclonal antibodies could be designed to block checkpoint receptors like CTLA-4 or PD-1, which are more abundant in non-translocation-associated sarcomas (such as six of the TCGA subtypes analyzed here, excluding SS).